Sabutoclax，50MG，SML3695-50MG，Sigma

Biochem/physiol Actions

Potent inhibitor against antiapoptotic Bcl-2 family proteins (Bcl-xL, Bcl-2, Mcl-1, Bfl-1) with anti-cancer efficacy in cultures and in vivo.



Sabutoclax (BI-97C1) is a potent inhibitor against antiapoptotic Bcl-2 family proteins (IC50 in nM against BH3 peptide binding = 310/Bcl-xL, 320/Bcl-2, 200/Mcl-1, 620/Bfl-1) that induces apoptosis in cancer cultures (EC50 in nM = 49/BP3, 130/PC3, 420/H460) with little cytotoxicity against bax-/-bak-/- cells. Sabutoclax anti-tumore efficacy in vivo, including a Bcl-2 transgenic model (42 mg/kg i.p. in mice expressing human Bcl-2 in splenic B-cells) and a M2182 prostate cancer xenograft model (1,3, 5 mg/kg q.o.d. i.p. in mice).